ImmunoINSIGHTS contract signed with global pharma

RNS Number : 5836D

Oncimmune Holdings PLC

04 March 2022

 

4 March 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

ImmunoINSIGHTS contract signed with leading top 10 global pharmaceutical company to profile biomarkers in CIDP

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces the signing of a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy ("CIDP").

Under the terms of this new contract, Oncimmune will utilise its specific high-throughput proprietary biomarker discovery platform, SeroTag^TM, to identify autoantibodies related to CIDP.   Specifically, ImmunoINSIGHTS will produce and validate CIDP specific antigens utilising the SeroTag^TM platform to screen clinical samples from CIDP patients for related autoantibodies.

CIDP is a rare type of autoimmune disease which attacks the myelin sheaths, the fatty coverings intended to insulate and protect nerves. Often referred to as Guillain-Barré syndrome (GBS) in its acute phase, CIDP is chronic, difficult to diagnose and can lead to permanent physical impairment if not treated in its earliest stages.

Dr Adam M Hill, CEO of Oncimmune said:  "We are pleased to announce this contract with another leading pharmaceutical company, adding to the growing list of global partners, working with us in the rare disease space where there is a real clinical need and opportunity to make a significant impact. This contract will make full use of the unique attributes of our SeroTag^TMplatform, and the competencies amongst our scientific colleagues, who are world leaders in autoimmune profiling.

"As is typical with SeroTag ^TM contracts, there is potential for the initial discovery work in autoantibodies to progress to further research and support for therapeutic development, creating and refining CIPD-specific NavigAID^TM panels using additional data and markers to guide drug development and inform patient and disease stratification."

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organisations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

What is SeroTag^TM?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag^TM is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag^TM analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID^TM disease-specific stratification panels. These precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

 

END

 

 

MSCUPURUWUPPGQW